New Data Reveals What’s Behind Delays and Denials in RA Care
This whitepaper presents a structured analysis of prior authorization outcomes for RA treatments requiring medical benefit coverage. It examines real-world access barriers from the perspective of payer decision patterns, documentation requirements, site of care, and plan type. Unlike claims-based studies or survey-based research, this analysis draws from actual prior authorization cases, providing a direct window into the real-world challenges faced by prescribers and patients alike.
Read the Report
Key takeaways
- Payer treatment of RA DMDs can vary by drug class — it’s important for pharmaceutical manufacturers to educate providers on payer requirements to avoid unnecessary delays to care caused by PA denials.
- The journey to care for rheumatoid arthritis patients is impacted by factors like site of care, insurance plan, and payer. Market Access teams must have a detailed understanding of these factors in order to best shape support strategies.